Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by XTX Topco Ltd

Key Points

• XTX Topco Ltd significantly increased its holdings in Moderna, acquiring an additional 27,237 shares, resulting in a total ownership of 32,049 shares valued at approximately $909,000.
• Moderna reported a quarterly earnings loss of ($2.13) per share, which was better than analysts' expectations of ($2.99), alongside a revenue of $142 million.
• The stock has recently seen its price target revised by several analysts, with JPMorgan setting a target of $26.00 and Barclays lowering theirs from $40.00 to $31.00, highlighting a cautious outlook on the company's performance.

XTX Topco Ltd raised its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 566.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,049 shares of the company's stock after acquiring an additional 27,237 shares during the period. XTX Topco Ltd's holdings in Moderna were worth $909,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in MRNA. Sentry Investment Management LLC acquired a new stake in Moderna during the first quarter worth about $31,000. Deseret Mutual Benefit Administrators increased its position in shares of Moderna by 53.3% during the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after purchasing an additional 392 shares during the period. Itau Unibanco Holding S.A. raised its stake in shares of Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after purchasing an additional 343 shares in the last quarter. Vega Investment Solutions acquired a new position in shares of Moderna in the 4th quarter valued at $45,000. Finally, Versant Capital Management Inc raised its stake in shares of Moderna by 408.9% in the 1st quarter. Versant Capital Management Inc now owns 1,593 shares of the company's stock valued at $45,000 after buying an additional 1,280 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on MRNA shares. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. William Blair restated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Cowen assumed coverage on Moderna in a research note on Sunday, July 13th. They issued a "hold" rating on the stock. Barclays lowered their target price on Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research note on Monday. Finally, Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday. Four investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $45.61.

Moderna Price Performance

MRNA stock traded down $0.17 during mid-day trading on Tuesday, reaching $27.47. The company had a trading volume of 6,150,202 shares, compared to its average volume of 9,033,059. The firm has a 50 day moving average of $29.27 and a 200 day moving average of $30.17. The company has a market capitalization of $10.69 billion, a PE ratio of -3.65 and a beta of 1.83. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna's revenue was down 41.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($3.33) EPS. Analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.